5685 results about "Antigen" patented technology

The disclosure relates to immune cells for treatment of blood cancer comprising an activator receptor comprising an extracellular ligand binding domain specific to an activator antigen expressed by blood cancer cells and an inhibitor receptor comprising an extracellular ligand binding domain specific to an inhibitor antigen expressed by non-cancerous blood cells.

The invention discloses a computer network security situation awareness system and method, and relates to the technical field of computer network security, and the method comprises the steps: generating a dynamic gene pool through an antigen-antibody matching algorithm based on an initial quantum trust vector, and building a mapping relation table of an antigen feature vector and an antibody defense strategy; triggering a quantum alarm according to an entanglement entropy mutation event in the real-time quantum state flow data, matching a biological antibody strategy corresponding to a current network attack feature based on a mapping relation table, and fusing the quantum alarm and the biological alarm to generate an attack path topological graph; the network security situation is perceived by analyzing the quantum state change of the abnormal node ID and combining an attack path topological graph and a dynamic gene pool. Quantum entanglement pairs are distributed to network nodes through the quantum key distribution center, and initial quantum trust vectors are generated, so that the unknown attack resisting capability of the network is remarkably improved, and efficient and accurate network security situation awareness is realized.

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

The invention discloses preparation of a targeting LYPD3 antibody and application of the targeting LYPD3 antibody in tumor immunotherapy. The antibody or antigen binding fragment thereof comprises a heavy chain variable region having CDR-H1, CDR-H2 and CDR-H3 and a light chain variable region having CDR-L1, CDR-L2 and CDR-L3 wherein CDR-H1, CDR-H2 and CDR-H3 comprise the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and CDR-L1, CDR-L2 and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

The invention discloses a citrullinated SAA polypeptide and application thereof in preparation of a rheumatoid arthritis diagnosis product, the amino acid sequence of the citrullinated SAA polypeptide is DKYFHA-Cit-GNYDAAK-Cit-GPGGA, through the polypeptide, the citrullinated autoantigen B cell epitope of SAA and a corresponding autoantibody, namely an anti-citrullinated SAA polypeptide antibody (anti-CAP), are identified. The expression level of anti-CAP in RA patients is obviously higher than that of other disease control groups and healthy groups, and the anti-CAP has better positive rate in early RA, ESR / CRP normal RA and anti-CCP antibody / RF negative RA, and provides a new strategy for diagnosis of RA.

The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to TNF-like ligand 1A (TL1A). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention, as well as to pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds; to methods for treating TL1A-mediated diseases or disorders, to use of the antibody or antigen-binding fragment thereof or pharmaceutical composition thereof for treating TL1A-mediated diseases or disorders, and to use of the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds for treating TL1A-mediated diseases or disorders.

The invention discloses an oligopeptide composition for inhibiting inclusion body formation and promoting Gag-Like protein nanoparticle self-assembly, the oligopeptide composition comprises a C-terminal oligopeptide and an N-terminal oligopeptide, the amino acid sequence of the N-terminal oligopeptide is as shown in SEQ ID NO: 1, and the amino acid sequence of the C-terminal oligopeptide is as shown in SEQ ID NO: 2. The oligopeptide composition can effectively avoid formation of a prokaryotic expression protein inclusion body and / or promote dissolution of prokaryotic expression protein, the oligopeptide composition is further utilized to be combined with HIV-1p24 and human endogenous retrovirus K capsid protein CA, nanoparticles are prepared respectively, and the oligopeptide composition can be used as a carrier for antigen surface display or drug transportation. The nanoparticles formed by the HIV-1 capsid protein p24 and the human HERV K CA have cavities which are obviously larger than those of ferritin, so that the nanoparticles have higher loading capacity; as an antigen display platform, the antibody also has good stability and wide applicability.

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same.Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided.The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.

The invention belongs to the technical field of software development and testing, and discloses an artificial intelligence-based software development automatic test case generation system, which is characterized in that an immune heuristic case self-repairing module is adopted, defects are regarded as antigens, antibody cases capable of being self-updated are generated by using a clone selection algorithm, and a gene rearrangement mechanism is automatically triggered when an interface is changed, so that the test efficiency is improved. The details of the use case are adjusted while the core detection logic is reserved; compared with a traditional method, the mechanism can realize use case dynamic adaptation without manual intervention, the maintenance workload is remarkably reduced, and the method is particularly suitable for a complex software system with frequent iteration; the space-time coupling test scene generation engine fuses dynamic scenes such as interaction and state transition of a module and short-time operation after precise coverage login by using a space-time convolutional network; the cross-dimension holographic use case synthesis module integrates multi-source data such as codes, hardware and user behaviors through tensor decomposition to generate a composite use case; functions and performance of software in a complex scene can be comprehensively verified, and test blind areas are remarkably reduced.

An antigen-binding molecule that binds to HER2, comprising (i) a HER2-binding moiety, and (ii) at least one linker-payload moiety, wherein the antigen-binding molecule comprises (a) DNA damage response (DDR) inhibitor moiety, and (b) a DNA topoisomerase I (TOP1) inhibitor moiety.

The invention discloses a hybridoma cell strain, a monoclonal antibody, a linear epitope antigen and application thereof, and relates to the field of genetic engineering, in particular to a hybridoma cell strain, a monoclonal antibody, a linear epitope antigen and application thereof. The preservation number of the hybridoma cell strain P27-A1 is CGMCC (China General Microbiological Culture Collection Center) No. 46352. The hybridoma cell strain P27-A1 is prepared from feline leukemia virus p27, and a monoclonal antibody secreted by the hybridoma cell strain P27-A1 recognizes a linear epitope antigen of feline leukemia virus p27 protein; the kit for the feline leukemia virus p27 comprises the monoclonal antibody A1 secreted by the hybridoma cell strain P27-A1. The monoclonal antibody secreted by the hybridoma cell strain can greatly improve the sensitivity of the p27 protein for detecting feline leukemia virus. The invention provides the monoclonal antibody secreted by the hybridoma cell strain for identification, and the monoclonal antibody can be used for preparing a diagnostic kit such as a colloidal gold test strip.

The invention belongs to the technical field of biology, and particularly relates to a group of paired monoclonal antibodies for resisting H9N2 subtype avian influenza viruses and a surface enhanced Raman spectroscopy rapid detection test strip established based on the antibodies. The paired monoclonal antibody comprises a labeled antibody 1E9 and a capture antibody 3C10 which are prepared by taking hemagglutinin protein of the H9N2 subtype avian influenza virus as antigens and can be specifically combined with the H9N2 subtype avian influenza virus. According to the invention, an SERS (Surface Enhanced Raman Scattering) probe Au-coated Pt-4ATP is used as a marker and is coupled with a labeled antibody 1E9 to prepare a labeled probe, and the labeled probe is paired with a capture antibody 3C10 to establish an SERS immunochromatography test strip. The test strip has a colorimetric and Raman dual interpretation mode, can be used for qualitative and quantitative detection, has the advantages of strong specificity, high sensitivity, good repeatability and stability and the like, is simple and rapid in clinical detection operation, and provides reliable technical support for on-site rapid screening of subtype viruses.

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of BRVA virus VP7 protein and an epitope and application of the monoclonal antibody. The invention provides a hybridoma cell strain (preservation number: CCTCC NO: C202570). A monoclonal antibody prepared from the hybridoma cell strain can be combined with VP7 protein of G6, G8 and G10 type BRVA; the antigen epitope amino acid sequence of the monoclonal antibody is SEQ ID NO: 1. The monoclonal antibody and the antigen epitope peptide provided by the invention have broad-spectrum neutralizing activity, and provide a new strategy and tool for prevention and control of BRVA.

This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

The invention provides a decellularized dermal matrix particle and a preparation method thereof, the preparation method comprises the steps of pretreatment, degreasing, virus inactivation, decellularization, grinding, crosslinking, freeze-drying and sterilization subpackaging, and solves the problems that the existing decellularized particle product is non-uniform in particle size, incomplete in decellularization, poor in injection effect and incapable of meeting the requirements of tissue repair and regeneration. The invention develops a product which is short in production cycle, relatively concentrated in particle size distribution, thorough in cell removal and complete in matrix function preservation, can effectively remove fat and viruses in animal skin, and has the advantages of being thorough in decellularization, short in time, high in efficiency, light in damage to dermal matrix, capable of removing antigens, capable of retaining a natural structure and capable of effectively guiding tissue regeneration. When the temperature of the freeze-dried particle dispersion liquid is reduced, the water binding capacity of the particles is reduced, free water in the prepared solution is increased, the particles naturally float and gather (dense at the upper part and sparse at the lower part), and the free water is in the lower layer and still has good dispersity after being sterilized.

The invention provides a power distribution network state sensing and control method and system based on an industrial Internet of Things, and relates to the technical field of power distribution network management, and the method comprises the steps: collecting data through an Internet of Things sensing node, constructing a dynamic coupling matrix, configuring a chaotic oscillator parameter to amplify a disturbance signal, and calculating a stability index to recognize a weak node. Antigen-antibody mapping is established, an antibody population is optimized to obtain a fault coping strategy, finally, an optimal control scheme is matched, a control instruction is issued, accurate sensing and efficient control over the operation state of the power distribution network are achieved, and the safety, stability and fault coping capacity of the power distribution network are improved.

Antibody-drug conjugates (ADC) useful for preventing, treating, and / or acting as an adjuvant in treating c-MET and / or EGFR-related diseases are disclosed. The ADCs comprise a bispecific antibody or antigen-binding fragment thereof comprising an arm specific for binding to EGFR and an arm specific for binding to c-MET conjugated to a cytotoxic drug.

The invention discloses a preparation method of a high-adsorbability aluminum hydroxide adjuvant for livestock, which comprises the following steps: when an aluminum chloride solution reacts with alkali liquor, generating a colloidal suspension by combining pH two-step adjustment with dispersant addition; and after instant high-speed shearing and room-temperature aging, performing ultrafiltration purification to remove salts, and finally performing moist heat sterilization to obtain the suspension morphological adjuvant. The adjuvant is high in antigen adsorption rate, low in 72-hour desorption rate, large in specific surface area, uniform in particle and suitable for vaccines of pigs, cattle and poultry, and the problems that a traditional adjuvant is low in adsorption rate and poor in stability are solved.

The invention relates to a monoclonal antibody aiming at respiratory syncytial virus F protein, a detection reagent based on the monoclonal antibody and application of the monoclonal antibody. According to the present invention, the monoclonal antibody or the antigen binding fragment thereof can specifically bind with the respiratory syncytial virus F protein with high affinity in vivo or in vitro, and has broad-spectrum effectiveness on various genotypes, such that the huge potential application value is provided in the clinical detection of respiratory syncytial virus infection.

The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.

The invention belongs to the technical field of living cell imaging, and discloses a living cell nucleic acid imaging system and method based on CRISPR (clustered regularly interspaced short palindromic repeats) and a nano antibody and application, the system comprises: a modified dCas protein expression vector containing n antigen polypeptide tags; the modified sgRNA and / or crRNA expression vector comprises a specific guide sequence; the fluorescent nano-antibody expression vector contains m fluorescent nano-antibody coding sequences which are connected in an operable manner, and fluorescent protein serving as an internal tag is inserted between nano-antibody splitting sites, can be combined with a polypeptide tag carried by dCas protein and can stably emit light; and the fluorescent nano antibody in a free state can be self-degraded, so that the fluorescent nano antibody does not emit fluorescence. According to the invention, the single-copy nucleic acid sequence, especially the imaging marker of the single-copy nucleic acid sequence in a living cell, can be visualized with single-molecule resolution and high signal-to-noise ratio.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.

The invention discloses a preparation method of a sandwich structure immunosensor based on surface enhanced Raman scattering and application of the sandwich structure immunosensor to detection of an anti-phospholipase A2 receptor antibody, and is characterized by comprising the following steps: sputtering silver ions on a cotton swab / ZIF-67 prepared by an in-situ growth method by adopting an ion sputtering method to obtain a cotton swab / ZIF-67 / Ag NPs composite material; the preparation method comprises the following steps: preparing an antigen solution, then adding the antigen solution into the antigen solution to obtain an immune substrate, adding a methylene blue aqueous solution into a silver nanoparticle solution for reaction, then connecting an anti-human PLA2R IgG antibody to obtain an immune probe, and finally dropwise adding a phosphate buffer solution containing an antibody to be detected onto the immune substrate, and dropwise adding the immune probe solution to the immune substrate adsorbed with the antibody to be detected to obtain the sandwich structure immunosensor based on surface enhanced Raman scattering. The method has the advantages of high sensitivity, good selectivity and strong stability.

The present invention relates to a pharmaceutical composition, which comprises an anti-CD73 (e.g., human CD73) antibody or an antigen-binding fragment thereof, and an anti-PD-1-anti-VEGFA bispecific antibody or an antigen-binding fragment thereof. Specifically, a heavy chain variable region of the anti-CD73 antibody comprises HCDR1-HCDR3 having amino acid sequences set forth in SEQ ID NOs: 15-17; and a light chain variable region of the antibody comprises LCDR1-LCDR3 having amino acid sequences set forth in SEQ ID NOs: 18-20.

The invention discloses an antibody or an antigen binding fragment thereof and a related product and application thereof, and relates to the field of immunodetection, the antibody comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is shown as SEQ ID NO: 28 and LCDR1, LCDR2 and LCDR3 in a light chain variable region of which the amino acid sequence is shown as SEQ ID NO: 29, the antibody can be specifically combined with HPV18 type E6-E7 fusion protein, and the antibody can be used for detecting the HPV18 type E6-E7 fusion protein. The method has the advantages of high detection sensitivity, good specificity, high accuracy, good repeatability and the like, and provides a way for effective detection of the HPV18 type E6-E7 fusion protein.

The invention relates to an anti-CK18 monoclonal antibody or an antigen binding fragment thereof, a detection reagent based on the anti-CK18 monoclonal antibody, and a preparation method and application of the anti-CK18 monoclonal antibody or the antigen binding fragment. According to the present invention, the anti-CK18 monoclonal antibody or the antigen binding fragment thereof can specifically bind with the CK18 protein or the fragment thereof with the high affinity, such that the low detection lower limit and the high detection sensitivity can be provided when the anti-CK18 monoclonal antibody or the antigen binding fragment thereof is used for the immunological detection of CK18; therefore, the monoclonal antibody or the antigen binding fragment of the monoclonal antibody has extremely high potential to be developed into an immunodetection antibody or a kit of the CK18 protein, or a diagnostic antibody or a diagnostic kit of diseases (such as NASH) related to abnormality of the CK18 protein (such as abnormal expression level), and has relatively great clinical application prospect and value.

This invention discloses a monoclonal antibody against human hepatitis B e antigen and its application, relating to the field of hepatitis B detection technology. In the heavy chain variable region of the monoclonal antibody, the amino acid sequences of the complementarity-determining regions (CDR1-3) are as shown in SEQ ID NO. 1-3 or have at least 95% homology with the sequences shown in SEQ ID NO. 1-3; in the light chain variable region, the amino acid sequences of the complementarity-determining regions (CDR1 and CDR3) are as shown in SEQ ID NO. 4 and 5 or have at least 95% homology with the sequences shown in SEQ ID NO. 4 and 5, and the amino acid sequence of the complementarity-determining region (CDR2) is FAS. The monoclonal antibody provided by this invention can effectively recognize natural hepatitis B e antigen, and the titer of the supernatant from B cell culture can reach 1:10000, making it fully applicable to the detection and research of human hepatitis B e antigen. The chemiluminescent reagent prepared using the monoclonal antibody described in this invention has advantages such as high specificity, strong anti-interference ability, high detection sensitivity, and good stability, with almost no missed detections, and can replace imported reagents.

The present invention provides an anti-human CD47 antibody or an antigen-binding fragment thereof, a preparation method and use. The present invention also provides an isolated polynucleotide encoding the antibody or antigen-binding fragment thereof and a vector comprising the isolated polynucleotide of the present invention. The present invention also provides the use of the antibody or antigen-binding fragment of the present invention in the preparation of a medicament for treating and / or preventing a disease that benefits from enhancing an immune response, wherein the disease is cancer.